Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer


Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the preclinical efficacy of NOV202 plus olaparib (Lynparza) in BRCA1/2-mutated prostate cancer cells.

NOV202 is an investigational microtubule-targeting and vascular disrupting agent that demonstrated anticancer activity and tumor growth suppression of certain cancers, such as pancreatic and ovarian cancers, in preclinical research. Olaparib is a PARP inhibitor that was FDA approved to treat men with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

During the 2021 EAU Congress, findings from a preclinical study evaluating the in vivo anticancer efficacy of NOV202 alone and in combination with olaparib in mouse models harboring BRCA1/2-mutated prostate cancer cells were presented. The results demonstrated that NOV202 alone induced significant anticancer effects in BRCA1/2-mutated prostate cancer xenografts. Additionally, NOV202 plus olaparib elicited significant synergistic effects in these xenografts. Notably, the synergistic effects observed after 3 weeks of treatment were maintained after 2 weeks of no treatment.

As such, NOV202 plus olaparib offers a promising new drug combination for patients with BRCA1/2-mutated advanced prostate cancer, says Sereti. Additional studies are needed to determine the mechanism of action of the synergistic activity observed preclinically, concludes Sereti.

Related Videos
Marc J. Braunstein, MD, PhD
Paul D. Nathan, MBBS, PhD, FRCP
Guru P. Sonpavde, MD
Arpita Desai, MD
Qian (Janie) Qin, MD
Melissa L. Johnson, MD
Adrienne Phillips, MD, MPH
Jeffrey S. Weber, MD, PhD
Manojkumar Bupathi, MD, MS
Mylin A. Torres, MD